147 related articles for article (PubMed ID: 36587066)
1. Immunomodulatory Functions of α-GalCer and a Derivative, α-Carba-GalCer.
Satoh M; Iwabuchi K
Methods Mol Biol; 2023; 2613():1-11. PubMed ID: 36587066
[TBL] [Abstract][Full Text] [Related]
2. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
3. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
4. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
Front Immunol; 2019; 10():352. PubMed ID: 30881361
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.
Guillaume J; Pauwels N; Aspeslagh S; Zajonc DM; Elewaut D; Van Calenbergh S
Bioorg Med Chem; 2015 Jul; 23(13):3175-82. PubMed ID: 26003341
[TBL] [Abstract][Full Text] [Related]
6. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
Berkers CR; Ovaa H
Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activities of amino acids functionalized α-GalCer analogues.
Ma W; Bi J; Zhao C; Zhang Z; Liu T; Zhang G
Bioorg Med Chem; 2020 Jan; 28(1):115141. PubMed ID: 31786009
[TBL] [Abstract][Full Text] [Related]
9. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
Front Immunol; 2019; 10():2355. PubMed ID: 31649670
[TBL] [Abstract][Full Text] [Related]
10. α-Galactosylceramide treatment before allergen sensitization promotes iNKT cell-mediated induction of Treg cells, preventing Th2 cell responses in murine asthma.
Chen Q; Guo X; Deng N; Liu L; Chen S; Wang A; Li R; Huang Y; Ding X; Yu H; Hu S; Nie H
J Biol Chem; 2019 Apr; 294(14):5438-5455. PubMed ID: 30745361
[TBL] [Abstract][Full Text] [Related]
11. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
[TBL] [Abstract][Full Text] [Related]
12. Invariant NKT cells facilitate cytotoxic T-cell activation via direct recognition of CD1d on T cells.
Qin Y; Oh S; Lim S; Shin JH; Yoon MS; Park SH
Exp Mol Med; 2019 Oct; 51(10):1-9. PubMed ID: 31653827
[TBL] [Abstract][Full Text] [Related]
13. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
14. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD1c enhances human invariant NKT cell activation by α-GalCer.
Fox LM; Miksanek J; May NA; Scharf L; Lockridge JL; Veerapen N; Besra GS; Adams EJ; Hudson AW; Gumperz JE
Cancer Immun; 2013; 13():9. PubMed ID: 23885215
[TBL] [Abstract][Full Text] [Related]
16. Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy.
Araki M; Miyake S; Yamamura T
Curr Med Chem; 2008; 15(23):2337-45. PubMed ID: 18855664
[TBL] [Abstract][Full Text] [Related]
17. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.
Nowak M; Arredouani MS; Tun-Kyi A; Schmidt-Wolf I; Sanda MG; Balk SP; Exley MA
PLoS One; 2010 Jun; 5(6):e11311. PubMed ID: 20593019
[TBL] [Abstract][Full Text] [Related]
18. Novel in vitro invariant natural killer T cell functional assays.
Balasko A; Graydon C; Fowke KR
J Immunol Methods; 2021 Dec; 499():113171. PubMed ID: 34706265
[TBL] [Abstract][Full Text] [Related]
19. Species-specific activity of glycolipid ligands for invariant NKT cells.
Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
